Search for a command to run...
Genprex, Inc.
Biotechnology
| Date | Politician | Asset | Action | Amount | Trade Price | 30D Price | 1M Return | Alpha | 1M Prediction |
|---|---|---|---|---|---|---|---|---|---|
Feb 5, 2026 |  Tim MooreR | Stock | Buy |
| $1,001 - $15,000 |
| $43.12 |
| $42.90 |
| -0.5% |
| +0.3% |
Dec 18, 2025 | Tim MooreR | Stock | Buy | $1,001 - $15,000 | $2.17 | $3.00 | +38.2% | +35.7% |
Nov 7, 2025 | Tim MooreR | Stock | Buy | $1,001 - $15,000 | $4.21 | $3.36 | -20.2% | -22.4% |
Oct 29, 2025 | Tim MooreR | Stock | Buy | $15,001 - $50,000 | $6.64 | $2.96 | -55.4% | -54.8% |
Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
12 Health Care Stocks Moving In Friday's After-Market Session
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics